Results 131 to 140 of about 98,145 (299)

Evidence‐Based Clinical Practice Guidelines for Metabolic Dysfunction–Associated Steatotic Liver Disease (MASLD) 2026

open access: yesHepatology Research, EarlyView.
ABSTRACT Metabolic dysfunction‐associated steatotic liver disease (MASLD) has emerged as the most prevalent chronic liver disease worldwide, with an increasing number of patients progressing to cirrhosis and hepatocellular carcinoma (HCC). Early identification of individuals at high risk for advanced fibrosis is essential for preventing liver‐related ...
Norio Akuta   +44 more
wiley   +1 more source

Prognostic Value of PALBI in Patients With Hepatocellular Carcinoma and Concurrent Chronic Kidney Disease: A Nomogram Development

open access: yesHepatology Research, EarlyView.
Patients with hepatocellular carcinoma (HCC) as well as chronic kidney disease (CKD) are high‐risk individuals, making it challenging to accurately predict their survival. We found that the PALBI grade model when combined with other patient's clinical and tumor‐related factors, forms a new and highly accurate prediction tool to estimate their ...
Jihye Lim   +2 more
wiley   +1 more source

Prevalence of Hepatitis C among Multi-transfused Thalassaemic Patients in Oman: Single centre experience

open access: yesSultan Qaboos University Medical Journal, 2015
Objectives: Regular blood transfusions are essential for patients with thalassaemia major. However, infections with hepatotropic viruses remain a major concern. The objective of this study was to evaluate the prevalence and characteristics of hepatitis C
Khalid Al-Naamani   +4 more
doaj   +2 more sources

Are We Aware of Hepatitis C Infection? HCV Results from the Tertiary Reference Center in the Aegean Region from Turkey

open access: yesInternational Journal of Clinical Practice
Background. With the advent of direct-acting antiviral agents, the rate of sustained virological response in the treatment of hepatitis C virus (HCV) infection has reached 100%. However, it has been observed that many patients still do not have access to
Gözde Derviş Hakim   +4 more
doaj   +1 more source

High false discovery rate of the Architect anti-HCV screening test in blood donors in Uganda and evaluation of an algorithm for confirmatory testing. [PDF]

open access: yesVox Sang, 2022
Lucey O   +8 more
europepmc   +1 more source

Era of direct acting anti-viral agents for the treatment of hepatitis C. [PDF]

open access: yes, 2018
Hepatitis C infection is universal and the most common indication of liver transplantation in the United States. The period of less effective interferon therapy with intolerable side effects has gone.
Ahmed, Monjur
core   +1 more source

Real‐world use of second‐generation integrase strand transfer inhibitors (INSTI) as switch therapy in the prospective ANRS‐CO3‐AquiVIH‐NA cohort

open access: yesHIV Medicine, EarlyView.
Abstract Objectives To characterize real‐world treatment switching in France to bictegravir (BIC or B) or dolutegravir (DTG)‐based regimens with a focus on treatment persistence, effectiveness (HIV‐1 RNA ≤50 copies/ml) and particular attention to the prevalence and incidence of comorbidities. Methods People living with HIV from the prospective ANRS‐CO3‐
O. Leleux   +15 more
wiley   +1 more source

Evaluation of the bioMérieux VIDAS HIV Duo Quick and Anti-HCV assays for dried blood spot based serosurveillance. [PDF]

open access: yesSci Rep, 2022
Cholette F   +11 more
europepmc   +1 more source

French guidelines on systemic treatments for moderate‐to‐severe psoriasis in adults: Update 2025

open access: yesJournal of the European Academy of Dermatology and Venereology, EarlyView.
New 2025 French guidelines update psoriasis management with revised algorithms integrating recent systemic therapies. They recommend methotrexate, adalimumab or ustekinumab as first‐line treatments and provide guidance for special psoriasis forms, comorbidities, pregnancy and long‐term management.
Marie Masson Regnault   +51 more
wiley   +1 more source

Home - About - Disclaimer - Privacy